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Sunmnary Quinine, the widely used antimalaria agent, was found to increase the cytotoxicity of epidoxo-
rubicin (epiDXR) in resistant DHD/K12 rat colon cancer cells in vitro. Quinine appeared as slightly less
effective than quinidine or verapamil for anthracycline potentiation but its weaker cardiotoxicity could
counterbalance this disadvantage in vivo. Serum from six patients treated by conventional doses of quinine
(25-30mgkg-'day-') was demonstrated to enhance the accumulation of epiDXR in DHD/K12 cells as
judged by fluorescence microscopy and HPLC assay (1.6 to 6-fold compared with control serum). In this
patients quinine concentrations in serum ranged from 4.4 to 10.1 g ml-'. Our results suggest that quinine
could be safely used as anthracycline resistance modifier in clinical practice.
Primary or acquired resistance to anthracyclines of human
cancers is partly associated with the overexpression of a
membrane glycoprotein (P 170) that effluxes drugs out of
cancer cells (Goldstein et al., 1989; Dalton et al., 1989).
Anthracycline resistance may be altered in vitro by a variety
of agents such as verapamil (Tsuruo et al., 1982), quinidine
(Tsuruo et al., 1984), amiodarone (Chauffert et al., 1986) or
cyclosporine (Slater et al., 1986). However, use of resistance
modifiers in clinical practice is still a problem due to the
toxicity of these agents that precludes the achievement of
effective concentrations in patient serum (Gottesman & Pas-
tan, 1989; Genne et al., 1990).
In this paper we report that quinine, the widely used
antimalaria drug, enhanced in vitro the cytotoxicity of epi-
doxorubicin in resistant colon cancer cells. Moreover, serum
of quinine treated patients was demonstrated to increase the
cellular accumulation of the anthracycline in resistant cells.
Materials and methods
Patients
The first patient (no. 1) was treated for a chloroquine-
resistant malaria; the other patients (nos2-6) were treated
after informed consent with a combination of quinine and
doxorubicin for anthracycline resistant tumours. Quinine was
given either per os or intravenously at a daily dose ordinarily
used for malaria treatment (24-30mgkg-' day-'). When
given per os, the daily dose of quinine was supplied in three
regular intakes. Intravenous treatment was given as contin-
uous infusion. Patient serum was collected at steady state
48 h at least after starting quinine administration. Peak and
trough plasma concentrations of quinine were determined in
two patients 2 and 8 h respectively after an oral intake.
Serum of one of the authors was used as control. After blood
collection, serum was centrifugated and stored at - 80C
until assay.
Cancer cells
The DHD/K12 cancer cell line was established in our labor-
atory from a chemically induced colon cancer in syngeneic
BDIX rats (Martin et al., 1975). Inherent resistance of DHD/
K12 cells to anthracyclines is partly related to a drug efflux
mechanism (Chauffert et al., 1984) which is efficiently inhi-
bited by amiodarone or verapamil (Chauffert et al., 1986).
Cells were grown as a monolayer adherent to the surface of
culture flasks. Culture medium was a mixture of Ham's FIO
medium and fetal bovine serum (10:1; V/V). For experi-
ments, cells were detached from the culture flasks by a
10 min treatment with EDTA (0.2 mg ml-') and tryspin
(2.5mg ml-') in Hank's medium without Ca2+ or Mg2+.
Drugs
Epidoxorubicin (epiDXR) was obtained from Farmitalia
Carlo Erba laboratories (Milan, Italy). EpiDXR was prefer-
red to doxorubicin because of its greater penetration and
cytotoxicity in vitro in DHD/K12 cells. Daunorubicin used as
internal standard for HPLC assay was purchased by Roger
Bellon laboratories (Neuilly, France). Quinine sulphate was
used for oral treatment and was obtained from Cooperation
Pharmacologique Franqaise (Melun, France). Quinine for-
miate was used for intravenous treatment and was obtained
from Vaillant-Defresne laboratories (Quinoforme, Paris,
France). Quinine hydrochloride, quinidine hydrochloride and
hydroquinidine hydrochloride used for in vitro experiments
were obtained from Sigma (La Verpilliere, France). Vera-
pamil hydrochloride was purchased from Biosedra labora-
tories (Malakoff, France).
Cytofluorescence study
The intracellular accumulation of epiDXR in DHD/K12 cells
was studied by UV illumination which induced a yellow-
orange fluorescence at the intracellular sites of anthracycline
localisation. We previously reported that low accumulation
of anthracyclines in nucleus of primary resistant DHD/K12
cells was related to a drug efflux mechanism (Chauffert et al.,
1984). In the presence of sufficient concentration of a drug
efflux inhibitor in incubation medium, anthracycline accum-
ulation increased in cancer cells and then a bright fluores-
cence was observed in nuclei. For microscopic examination,
DHD/ K12 cells were cultivated for 24 h on glass coverslips
then exposed for I h to epiDXR (5 jgml-') diluted in
patient or control serum. After rinsing with cold phosphate
buffered saline (PBS), cells were examined under an UV
fluorescence microscope (Leitz, Weitzlar, FR Germany).
EpiDXR uptake in cancer cells
DHD/K12 cells in suspension were incubated for 1 h at 37°C
with epiDXR (5 or g ml-') diluted in patient or control
serum. After rinsing twice with cold PBS and centrifugation,
cells pellets were mixed with daunorubicin diluted in borate
buffer, pH!9.4. Anthracyclines were extracted by a chloro-
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form-methanol mixture (4:1, V/V). The organic phase was
evaporated under a nitrogen stream; the dry residue was
diluted in mobile phase and injected into an HPLC appar-
atus; the mobile phase was a mixture of acetonitrile and
formiate buffer, pH 4 (1:2, V/V); the stationary phase was a
microbondapak C18 column (Waters Associates, Millford,
USA). Drugs were detected by fluorimetry at excitation and
emission wavelengths of 480 and 560 nm respectively.
In vitro drug-sensitivity test
Enhancement of epiDXR cytotoxicity induced by verapamil,
quinidine or quinine was compared by an in vitro test using a
long exposure to anthracycline. DHD/K12 cells (I x 104 cells
in 200 jlI culture medium) were seeded in the wells of a
microculture plate (9 x 12 wells) in presence of epiDXR
(0.25 jg ml-') combined with various concentrations of the
resistance modifier agents. After 72 h, cell survival was deter-
mined by a methylene blue colorimetric assay soon described
elsewhere (Martin et al., 1982; Oliver et al., 1989). Surviving
cells remained adherent to the well bottom whereas dead cells
were detached in culture medium. After rinsing wells with
PBS, adherent cells were fixed for 15 min by pure ethanol
then stained by methylene blue (1% in PBS); dye in excess
was flushed away with abundant tap water. Dye fixed to cell
proteins was eluted by a mixture of HCI 0.1 N and pure
ethanol (1: 1. V/V). Optical density (OD) was measured in
each well at 630 nm by an automatic spectrophotometer; it
has been previously demonstrated that OD is proportional to
the number of living cells remaining attached on the bottom
of each well at the end of experiment.
Measurement ofquinine concentration in patient serum
Patient serum was mixed with borate buffer, 0.5 M, pH 9.8,
and hydroquinidine used as internal standard. Extraction was
performed by a mixture of dichloromethane and isoamylic
alcohol (98:2, V/V). The organic phase was evaporated
under a nitrogen stream. The dry residue was dissolved in the
mobile phase and injected into an HPLC apparatus. The
mobile phase was a mixture of acetonitrile and potassium
phosphate buffer, pH 3.8 (1:4, V/V). The stationary phase
was a Novapak C18 5 j column. Drugs were detected by
fluorimetry at excitation and emission wavelengths of 350
and 440 nm respectively.
Results
When DHD/K12 cells were treated for 72 h with epiDXR
(0.25 jg ml-') in combination with resistance modifiers, IC50
values were obtained for 0.5fjgml-' verapamil, 1 igml-'
quinidine and 2 jig ml-' quinine. Cell death was almost com-
plete in the presence of 2jgml-' verapamil, 4jig ml-'
quinidine or 6tigml-' quinine (Figure 1).
Only a weak and inhomogenous fluorescence was seen in
cell nuclei after a 1 h incubation of DHD/K12 cells in control
serum supplemented with epiDXR (5 jigml-'). In contrast,
we observed an intense and homogenous nuclear fluorescence
when cells were treated with epiDXR 5 j.g ml-' diluted in all
the sera of quinine treated patients (Figure 2).
Fluorescence microscopy allowed the demonstration of the
rapid reversibility of the inhibition of anthracycline efflux by
quinine. When DHD/K12 cells were incubated for 1 h in
Ham's FIO medium supplemented with quinine 5jigml-l
and epiDXR 5fjgml-', cell nuclei were brightly fluorescent;
however, nuclear fluorescence disappeared almost completely
in less than I h when cells were incubated again in Ham's
FIO medium supplemented with epiDXR 5figml-' but with-
out quinine.
EpiDXR content in DHD/K12 cells was from 1.6 to 5.4-
fold greater after a 1 h incubation in serum ofquinine treated
patients comparatively to control serum (Table I). Quinine
concentrations in patient serum ranged from 4.4 to 10.1 jig
ml-' (Table II). Stability of quinine concentrations in patient
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Figure 1 Cytotoxicity of epiDXR (0.25fjgmIm
1 for 72h) on
DHD/K12 cells in presence of quinine (m), quinidine (-) or
verapamil (*). No cytotoxicity was registered at considered con-
centrations for verapamil, quinidine or quinine used alone with-
out epiDXR. Each point is the mean of three determinations
(maximal standard deviation = 3%).
a
b
Figure 2 Fluorescence microscopic study of DHD/K12 cells
after 1 h incubation with 5jug ml ' epiDXR in presence of cont-
rol serum (a) or serum from a quinine treated patient (b)
( x 520).
serum was demonstrated by the weak difference between
peak and trough concentrations in two patients treated with
oral quinine.
Discussion
Although quinine appeared to be slightly less effective than
quinidine or verapamil for the circumvention in vitro of the
anthracycline resistance of rat colon cancer cells, its lower
cardiotoxicity could be a considerable advantage for its use
as multidrug resistance modifier in clinical oncology. SerumQUININE FOR ANTHRACYCLINE RESISTANCE 397
Table I EpiDXR accumulation in DHD/K12 cells in presence of
serum from quinine treated patients
EpiDXR cell content (ng x 10'- cells)a
EpiDXRconcentrationinincubationserum(Itgml')
Patient 5 10
Control 170 210
1 430 870
2 280 390
3 580 1060
4 930 1250
5 800 1320
6 260 480
aMean ofthree determinations (maximal standard deviation = 9%).
Table II Quinine concentrations in patient serum
Serum
Daily dose concentration
Patient (mgkg- I day') Way (gAgml')
1 Male Malaria 25 p.o. 4.8
2 Male Hepatoma 25 p.o. 4.4
3 Male Undifferentiated 25 p.o. Peak: 10.1
carcinoma Trough: 9.9
4 Female Ovarian 25 p.o. Peak: 7.3
carcinoma Trough: 7.0
5 Male Non-Hodgkin's 25 i.v. 4.4
lymphoma
6 Male Acute non- 30 i.v. 6.9
lymphocytic
leukaemia
p.o., per os; i.v. intravenous infusion.
of quinine treated patients was demonstrated to increase the
epiDXR accumulation in DHD/K12 anthracycline resistant
cells; such an enhancing effect was obtained for quinine
concentrations ranging from 4.4 to 1O.I g mlh' in patient
serum. In this work, the daily dose of quinine was 25 or
30 mg kg-' day-' as usually recommended for the treatment
of malaria (Hall, 1976). Higher quinine concentrations
(10-15fig ml-') could be reached with a daily dose of 35 mg
kg-' as for patients with cerebral malaria (White et al.,
1982). Risk of severe poisoning, mainly transient or perma-
nent visual deficit, occurs only when serum levels exceeded
15 tg ml-' (Boland, 1985). Comparatively serum concentra-
tions of quinidine that are recommended for treatment of
cardiac dysrytmias ranged from 3 to 5 tLg ml-' with risk of
severe blockade of auriculoventricular conduction above
8 tLg ml-' (Holford et al., 1981). In the study of Benson et al.
(1985), which evaluated the tolerance of verapamil given by
continuous infusion (0.12 tg kg-' h-') in association with
vinblastine, the maximal tolerated concentration was 0.29jig
ml-' in serum. Binding of resistance modifiers to serum
proteins must also be considered before extrapolating the
results of in vitro studies to clinical practice. However, no
dramatic difference is registered in the binding of the present
resistance modifiers to serum proteins: 90% for verapamil
(Schomerus et al., 1976), 75-95% for quinidine (Ochs et al.,
1980) and quinine (Silamut et al., 1985). Stability of quinine
concentration in patient serum related to its long half-life
(10 h) appears also as a propitious property for its use as a
circumventing agent of the anthracycline resistance in future
clinical studies.
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